Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | PDE9A | O76083 | 1/20 | 0.42 |
| ▸ | B3GNT2 | Q9NY97 | 4/20 | 0.40 |
| ▸ | PGR | P06401 | 7/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21156813 | 0.83 | LMNA (0.43) | POLBPDE9AMAOBMLYCDMEN1 | |
| SCHEMBL24815335 | 0.82 | POLB (0.64) | POLBB3GNT2PGRMEN1KMT2A | |
| SCHEMBL30048927 | 0.82 | POLB (0.64) | POLBB3GNT2PGRMEN1KMT2A | |
| SCHEMBL5836929 | 0.81 | MLYCD (0.40) | POLBPDE9AB3GNT2MLYCDMEN1 | |
| SCHEMBL27295279 | 0.80 | POLB (0.68) | POLBB3GNT2PGRKMT2AKDM4E | |
| SCHEMBL31473364 | 0.80 | POLB (0.68) | POLBB3GNT2PGRKMT2AKDM4E | |
| SCHEMBL5837301 | 0.78 | MEN1 (0.52) | POLBMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL5836240 | 0.76 | ALDH1A1 (0.58) | PGRKDM4EALDH1A1 | |
| SCHEMBL4345749 | 0.76 | ALDH1A1 (0.57) | POLBMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL6054650 | 0.76 | HPD (0.48) | MLYCDMEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1708709-A1 | METHODS OF TREATING ACUTE INFLAMMATION IN ANIMALS WITH p38 MAP KINASE INHIBITORS | Pfizer Products Incorporated (US) | 2006-10-11 | — | — | EP | disclosed |
| US-20050153985-A1 | Methods of treating acute inflammation in animals with p38 map kinase inhibitors | KEHRLI MARCUS E JR (US) | 2005-07-14 | — | — | US | disclosed |
| WO-2005060967-A1 | METHODS OF TREATING ACUTE INFLAMMATION IN ANIMALS WITH p38 MAP KINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153985-A1 | Methods of treating acute inflammation in animals with p38 map kinase inhibitors | MAPK1, MAPKAPK2, MAP3K2 | POLB 4671/4885PDE9A 2344/4885B3GNT2 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.